Table. . Overview of 18 cases of SARS-CoV-2 infection caused by the Omicron variant, Japan, November 29–December 18, 2021*.
Case no. | Patient age, y/sex | Disease severity | Vaccine, no. doses (type) | Duration of symptoms, d | Lowest Cq values (days after diagnosis, days after symptom onset) | Virus isolation, since diagnosis (days)‡ |
---|---|---|---|---|---|---|
1 | 39/M | Mild | 2 (M, M) | 5 | 21.6 (3, 3) | Positive (3) |
2 | 30/M | Asymptomatic | 2 (M, M) | NA | 25.3 (5, NA) | Positive (5) |
3 | 25/M | Mild | 2 (P, P) | 6 | 23.2 (4, 3) | Negative |
4 | 46/M | Mild | 3 (J, P, P) | 11 | 24.7 (9, 11) | Positive (6) |
5 | 50/M | Asymptomatic | 2 (P, P) | NA | 23.1 (5, NA) | Positive (5) |
6 | 31/M | Mild | 2 (P, P) | 5 | 25.4 (0, 0) | Negative |
7 | 47/M | Asymptomatic | 2 (P, P) | NA | 34.2 (9, NA) | Negative |
8 | 33/F | Mild | 2 (M, M) | 12 | 32.4 (0, 1) | Negative |
9 | 64/M | Mild | 2 (P, P) | 4 | 23.9 (0, −1) | Positive (0) |
10 | 42/M | Mild | 2 (M, M) | 4 | 27.0 (0, −1) | Negative |
11 | 49/M | Mild | 2 (M, M) | 5 | 26.5 (0, −1) | Positive (8) |
12 | 31/M | Mild | 2 (M, M) | 4 | 25.4 (5, 4) | Positive (7) |
13 | 50/M | Mild | 2 (M, M) | 6 | 24.7 (5, 7) | Positive (5) |
14 | 30/F | Mild | 2 (M, M) | 11 | 30.0 (0, 2) | Negative |
15 | 27/M | Mild | 2 (P, P) | 8 | 25.8 (6, 10) | Negative |
16 | 23/M | Mild | 2 (P, P) | 5 | 18.7 (3, 4) | Positive (3) |
17 | 47/M | Mild | 2 (M, M) | 6 | 24.2 (7, 7) | Positive (0) |
18 | 38/M | Mild | 2 (P, P) | 6 | 29.0 (7, 8) | Negative |
*The consensus sequences of the viral genome have been uploaded to GISAID (https://www.gisaid.org) (identification nos. EPI_ISL_6913953, EPI_ISL_6914908, EPI_ISL_7194610, EPI_ISL_7834392, EPI_ISL_7860184, EPI_ISL_7860185, EPI_ISL_7860188, EPI_ISL_7860189, EPI_ISL_7860190, EPI_ISL_7860193, EPI_ISL_7860197, EPI_ISL_7889642, EPI_ISL_7889643, EPI_ISL_8096984, EPI_ISL_8096995, EPI_ISL_8605240, EPI_ISL_8605241, EPI_ISL_8605242). Cq, quantification cycle; J, Johnson & Johnson; M, Moderna; NA, not available; P, Pfizer/BioNTech; SARS-CoV-2, severe acute respiratory syndrome. coronavirus 2.